Publications by authors named "M J Axe"
Intra-articular corticosteroid injections, such as triamcinolone acetonide (TA), are commonly used by clinicians to manage joint synovial inflammation. However, due to conflicting evidence in literature, there is a fear among clinicians that the injections may be harmful to otherwise healthy cartilage in young patients. The purpose of this study was to evaluate the effects of TA on young, healthy chondrocytes.
View Article and Find Full Text PDFArticle Synopsis
- The study compared patient-reported outcomes between participants following a specific treatment algorithm (Delaware-Oslo ACL Cohort) vs. those receiving usual care after ACL reconstruction.
- Results showed that participants in the Delaware-Oslo group reported significantly better outcomes in terms of knee symptoms and function, with more individuals achieving satisfactory health states.
- Overall, the findings suggest that a structured rehabilitation approach leads to better long-term results after ACL surgery compared to standard care practices.
Background: Impairments and dysfunction vary considerably after anterior cruciate ligament (ACL) injury, and distinct subgroups may exist.
Purpose: (1) To identify subgroups of patients with ACL injury who share common trajectories of patient-reported knee function from initial presentation to 5 years after a treatment algorithm where they chose either ACL reconstruction (ACLR) plus rehabilitation or rehabilitation alone. (2) To assess associations with trajectory affiliation.
Importance: The effectiveness of monoclonal antibodies (mAbs), casirivimab-imdevimab and sotrovimab, is unknown in patients with mild to moderate COVID-19 caused by the SARS-CoV-2 Delta variant.
Objective: To evaluate the effectiveness of mAb against the Delta variant compared with no mAb treatment and to ascertain the comparative effectiveness of casirivimab-imdevimab and sotrovimab.
Design, Setting, And Participants: This study comprised 2 parallel studies: (1) a propensity score-matched cohort study of mAb treatment vs no mAb treatment and (2) a randomized comparative effectiveness trial of casirivimab-imdevimab and sotrovimab.
Article Synopsis
- Monoclonal antibodies (mAbs) like bamlanivimab, bamlanivimab-etesevimab, and casirivimab-imdevimab are effective in reducing hospitalization and death in patients with mild to moderate COVID-19, but their comparative effectiveness is unclear.
- In a trial involving 1,935 patients, each mAb treatment resulted in a median of 28 hospital-free days, with very low mortality rates across the treatments.
- The analysis showed that bamlanivimab was likely inferior to the other two treatments, while bamlanivimab-etesevimab and casirivimab-imdevimab were statistically similar.